Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage

Table 3 Self-rated health status and health utility as measured by the EQ-5D-5L by patient group

	Group 1	Group 2	Group 3	Between-group differences
	Group 1	Group 2	Group 3	Fisher p value
Utility weighted by the England tariff	0.809 (0.170) (n = 86)	0.818 (0.181) (n = 108)	0.695 (0.262) (n = 97)	< 0.001
Visual analogue scale	72.74 (18.39) (n = 89)	77.01 (17.53) (n = 108)	65.82 (22.86) (n = 99)	< 0.001

Higher scores reflect higher levels of HRQoL. n, numbers shown where data were not available for all patients. See Additional file 1: Table S5 for index values estimated using the UK crosswalk tariff

ISSN: 1477-7525